Chiesi bets $160M on Gos­samer Bio’s make-or-break late-stage PAH drug

Gos­samer Bio has lined up a part­ner to foot the de­vel­op­ment and com­mer­cial­iza­tion bill for its make-or-break late-stage drug, ex­pand­ing Phase 3 plans and paving the way for its launch out­side the US.

Ital­ian phar­ma Chiesi will pay Gos­samer $160 mil­lion to kick off the col­lab­o­ra­tion. In ad­di­tion to that ini­tial pay­ment — dubbed a “de­vel­op­ment re­im­burse­ment” — Chiesi will al­so split fu­ture costs for the can­di­date, ser­a­lu­tinib, and com­mit a to­tal of $226 mil­lion in reg­u­la­to­ry and sales mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER